Houston, Texas – Moleculin Biotech, Inc. held their Q3 2024 Earnings Conference Call on November 11, 2024, at 8:30 AM. The conference call provided an update on the company’s financial performance and key developments. Company participants included Jenene Thomas, Investor Relations; Walter Klemp, Chairman and CEO; John Paul Waymack, Senior CMO; and Jonathan Foster, EVP and CFO.

During the call, the team discussed Moleculin’s current intentions, beliefs, and future projections, emphasizing the importance of transparency and compliance with Federal Securities Laws. They highlighted potential risks and uncertainties, urging listeners not to rely solely on forward-looking statements. The company’s periodic reports filed with the Securities and Exchange Commission were referenced for more in-depth information.

Investors and analysts, including Jonathan Aschoff from Roth MKM, Jason McCarthy from Maxim Group, and Vernon Bernardino from H.C. Wainwright, participated in the conference call. The operators reminded all participants that the call was being recorded and announced that a question-and-answer session would follow the formal presentation.

Jenene Thomas, as the host, welcomed all participants to the conference call and emphasized the significance of the information shared. She encouraged listeners to review Moleculin’s periodic reports and SEC filings for a comprehensive understanding of the company’s operations and future outlook. Additionally, she mentioned that certain data presented during the call was sourced from third-party studies, publications, and the company’s own research.